®
PRODUCT DATA SHEET
APP ∆C31 ELISA kitR2W ADI-900-227 First-to-market, sensitive ELISA kit to quantify APP ∆C31, an important amyloid precursor protein fragment with a unique pro-apoptotic mechanism leading to Alzheimer s disease. Product Number/Sizes ADI-900-227-0001
96 wells
®
AMP D Certified - can be combined with ENZ-ABS257 and ENZ-KIT-100 to amplify signal. • • • • •
Sensitive - measure as little as 0.92 pM of APP ∆C31 Quantitative - fully quantitative results surpass semi-quantitative Western blot analysis Higher Throughput - results from up to 38 samples in duplicate in just 2 hours Specific - low cross-reactivity to similar APP isoforms AMP'D® Certified - obtain more reliable analysis of samples with low APP ∆C31 concentrations with a 10-fold increase in sensitivity (from 0.92 pM to 0.094 pM)
The APP ∆C31 ELISA kit is a complete, colorimetric, immunometric immunoassay kit for the quantitative determination of human APP ∆C31 in cell lysate and cerebral spinal fluid samples with results in just 2 hours. The kit provides a simple and easy-to-use way for the specific measurement of the neo-APP fragment from the APP ∆C31 cleavage event which when combined with measurements of other Alzheimer s disease associated proteins (Aβ40/42, sAPPα and tau/p-tau) could prove a useful biomarker for the diagnosis and monitoring of Alzheimer s disease progression.
Product Specifications ALTERNATIVE NAME:
Amyloid precursor protein, APP neo
SENSITIVITY:
0.92 pM (range 11.72 - 1500 pM)
ASSAY TIME:
~2 hours
APPLICATIONS:
ELISA, Colorimetric detection
APPLICATION NOTES:
For the quantitative determination of human APP ∆C31 in cell lysate, cerebral spinal fluid, plasma and serum samples. Sequence alignments indicate multiple species are probable.
SPECIES REACTIVITY:
Human
SHIPPING:
Blue Ice Not Frozen
LONG TERM STORAGE:
+4°C
KIT/SET CONTAINS:
Microtiter Plate, Assay Buffer, Standard, Detector Antibody, Antibody-HRP-conjugate, TMB Substrate, Stop Solution, Wash Buffer Concentrate
SCIENTIFIC BACKGROUND:
Alzheimer′s disease (AD) is a progressive neurodegenerative disease characterized by the senile plaques, neurofibrillary tangles and loss of synapses and neurons. AD has been largely viewed as a disease of toxicity being mediated by the accumulation of the amyloid beta (Aβ) peptide as plaques within the brain resulting in damage to brain cells from the binding of damaging metals, reactive oxygen species production and direct damage to cellular membranes. Recent research has suggested that the Aβ peptide is a multifunctional peptide with non-pathological effects and that its association with AD is in conjunction with its roles in combination with other proteins such as the amyloid precursor protein (APP) resulting in the imbalance between the processes of memory formation and normal forgetting. It is through the interactions of the Aβ peptide with APP that the Aβ peptide itself can affect normal modulation and signaling of APP resulting in its indicated role in the pathogenesis of AD via signaling effects rather than chemical or physical effects.
For Research Use Only, Not for Human GLOBAL HEADQUARTERS
EUROPE/ASIA
Enzo Life Sciences, Inc. 10 Executive Blvd Farmingdale, NY 11735 USA T 1-800-942-0430 T 1-631-694-7070 F 1-610-941-9252 E info-usa@enzolifesciences.com www.enzolifesciences.com
Enzo Life Sciences (ELS) AG Industriestrasse 17, Postfach CH-4415 Lausen Switzerland T +41/061 926 89 89 F +41/061 926 89 79 E info-ch@enzolifesciences.com www.enzolifesciences.com